126 related articles for article (PubMed ID: 16249244)
1. A statistical analysis of the interrelationships between disease activity in different systems in systemic lupus erythematosus.
Allen E; Farewell VT; Isenberg DA; Gordon C
Rheumatology (Oxford); 2006 Mar; 45(3):308-13. PubMed ID: 16249244
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study.
Stoll T; Sutcliffe N; Mach J; Klaghofer R; Isenberg DA
Rheumatology (Oxford); 2004 Aug; 43(8):1039-44. PubMed ID: 15161983
[TBL] [Abstract][Full Text] [Related]
3. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.
Hanly JG; McCurdy G; Fougere L; Douglas JA; Thompson K
J Rheumatol; 2004 Nov; 31(11):2156-62. PubMed ID: 15517627
[TBL] [Abstract][Full Text] [Related]
4. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus.
Brunner HI; Gladman DD; Ibañez D; Urowitz MD; Silverman ED
Arthritis Rheum; 2008 Feb; 58(2):556-62. PubMed ID: 18240232
[TBL] [Abstract][Full Text] [Related]
5. Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus.
Zonana-Nacach A; Yañez P; Jiménez-Balderas FJ; Camargo-Coronel A
Lupus; 2007; 16(12):997-1000. PubMed ID: 18042596
[TBL] [Abstract][Full Text] [Related]
6. Anti-nucleosome and anti-chromatin antibodies are present in active systemic lupus erythematosus but not in the cutaneous form of the disease.
Souza A; da Silva LM; Oliveira FR; Roselino AM; Louzada-Junior P
Lupus; 2009 Mar; 18(3):223-9. PubMed ID: 19213860
[TBL] [Abstract][Full Text] [Related]
7. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
Mok CC; Ho LY; Cheung MY; Yu KL; To CH
Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
[TBL] [Abstract][Full Text] [Related]
8. The effect of menopause on disease activity in systemic lupus erythematosus.
Urowitz MB; Ibañez D; Jerome D; Gladman DD
J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295
[TBL] [Abstract][Full Text] [Related]
9. Role of specialty care in the management of patients with systemic lupus erythematosus.
Urowitz MB; Kagal A; Rahman P; Gladman DD
J Rheumatol; 2002 Jun; 29(6):1207-10. PubMed ID: 12064836
[TBL] [Abstract][Full Text] [Related]
10. Adrenomedullin--a potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus.
Mak A; Cheung BM; Mok CC; Leung R; Lau CS
Rheumatology (Oxford); 2006 Oct; 45(10):1266-72. PubMed ID: 16595522
[TBL] [Abstract][Full Text] [Related]
11. Systemic lupus erythematosus in a multiethnic US cohort LUMINA LI: anaemia as a predictor of disease activity and damage accrual.
Bertoli AM; Vilá LM; Apte M; Fessler BJ; Bastian HM; Reveille JD; Alarcón GS;
Rheumatology (Oxford); 2007 Sep; 46(9):1471-6. PubMed ID: 17650522
[TBL] [Abstract][Full Text] [Related]
12. Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual.
Vilá LM; Alarcón GS; McGwin G; Bastian HM; Fessler BJ; Reveille JD;
Arthritis Rheum; 2006 Oct; 55(5):799-806. PubMed ID: 17013840
[TBL] [Abstract][Full Text] [Related]
13. The impact of race and ethnicity on disease severity in systemic lupus erythematosus.
Crosslin KL; Wiginton KL
Ethn Dis; 2009; 19(3):301-7. PubMed ID: 19769013
[TBL] [Abstract][Full Text] [Related]
14. Effect of severe neuropsychiatric manifestations on short-term damage in systemic lupus erythematosus.
Fragoso-Loyo HE; Sánchez-Guerrero J
J Rheumatol; 2007 Jan; 34(1):76-80. PubMed ID: 17143970
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients.
Zhang CY; Lu LJ; Li FH; Li HL; Gu YY; Chen SL; Bao CD
J Clin Rheumatol; 2009 Apr; 15(3):111-6. PubMed ID: 19300290
[TBL] [Abstract][Full Text] [Related]
16. Participatory patient-physician communication and morbidity in patients with systemic lupus erythematosus.
Ward MM; Sundaramurthy S; Lotstein D; Bush TM; Neuwelt CM; Street RL
Arthritis Rheum; 2003 Dec; 49(6):810-8. PubMed ID: 14673968
[TBL] [Abstract][Full Text] [Related]
17. Summarizing disease features over time: II. Variability measures of SLEDAI-2K.
Ibañez D; Gladman D; Urowitz M
J Rheumatol; 2007 Feb; 34(2):336-40. PubMed ID: 17183620
[TBL] [Abstract][Full Text] [Related]
18. Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus.
Tisseverasinghe A; Lim S; Greenwood C; Urowitz M; Gladman D; Fortin PR
Arthritis Rheum; 2006 Jul; 54(7):2211-9. PubMed ID: 16802357
[TBL] [Abstract][Full Text] [Related]
19. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
Petri M; Stohl W; Chatham W; McCune WJ; Chevrier M; Ryel J; Recta V; Zhong J; Freimuth W
Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552
[TBL] [Abstract][Full Text] [Related]
20. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations.
Magalhães MB; da Silva LM; Voltarelli JC; Donadi EA; Louzada-Junior P
Scand J Rheumatol; 2007; 36(6):442-7. PubMed ID: 18092265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
